Low free T3 levels associated with COVID-19 mortality, ICU a
Now open: Certificate Course in Management of Covid-19 by Govt. Of Gujarat and PlexusMDKnow more...Now open: Certificate Course in Management of Covid-19 by Govt. Of Gujarat and PlexusMDKnow more...
Get authentic, real-time news that helps you fight COVID-19 better.
Install PlexusMD App for doctors. It's free.
Euthyroid adults hospitalized with COVID-19 who had lower free triiodothyronine levels had more ICU admissions, mechanical ventilation and mortality compared with those with higher levels, according to researchers.

Precise risk stratification and triage of COVID-19 patients are essential in the setting of an overwhelming pandemic burden. Clinical observation has shown a somewhat high prevalence of sick euthyroid syndrome among patients with COVID-19. This study aimed to evaluate the predictive value of free triiodothyronine (FT3) at the clinical presentation of COVID-19 for disease severity and death.

This retrospective cohort study was based on electronic medical records. The primary outcome measure was death during hospitalization; secondary outcomes included hospitalization in intensive care, mechanical ventilation, and length of hospitalization.

-- Of a total of 577 polymerase chain reaction-positive patients with COVID-19, 90 had at least 1 measurement of thyroid-stimulating hormone, free thyroxine, and FT3 within 3 days of presentation.

-- After applying strict exclusion criteria, 54 patients were included in the study. Patients in the lowest tertile of FT3 had significantly higher rates of mortality, mechanical ventilation and intensive care unit admission.

-- In multivariate analyses adjusted for age, Charlson comorbidity index, creatinine, albumin, and white blood cell count. FT3 remained a significant independent predictor of death.

Conclusively, FT3 levels can serve as a prognostic tool for disease severity in the early presentation of COVID-19.

Source: https://www.endocrinepractice.org/article/S1530-891X(21)00006-9/fulltext